Abstract
Two middle aged female patients developed hallucinations and severe confusion with paranoid features during oral tocainide administration at recommended dosage levels. Both patients had evidence of impaired renal function. Symptoms were provoked on re-challenge in the first patient. In the second patient the tocainide blood level was higher than the recommended therapeutic range. Both patients reverted to their normal mental state on withdrawal of the drug.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Haffajee C. I., Alpert J. S., Dalen J. E. Tocainide for refractory ventricular arrhythmias of myocardial infarction. Am Heart J. 1980 Dec;100(6 Pt 2):1013–1016. doi: 10.1016/0002-8703(80)90206-9. [DOI] [PubMed] [Google Scholar]
- Horn H. R., Hadidian Z., Johnson J. L., Vassallo H. G., Williams J. H., Young M. D. Safety evaluation of tocainide in the American Emergency Use Program. Am Heart J. 1980 Dec;100(6 Pt 2):1037–1040. doi: 10.1016/0002-8703(80)90210-0. [DOI] [PubMed] [Google Scholar]
- Rubino M., Jackson E. Severe paranoia with concomitant tocainide and propranolol therapy. Clin Pharm. 1982 Mar-Apr;1(2):177–179. [PubMed] [Google Scholar]
- Ryan W., Engler R., LeWinter M., Karliner J. S. Efficacy of a new oral agent (tocainide) in the acute treatment of refractory ventricular arrhythmias. Am J Cardiol. 1979 Feb;43(2):285–291. doi: 10.1016/s0002-9149(79)80017-x. [DOI] [PubMed] [Google Scholar]